Abstract | INTRODUCTION: MATERIALS AND METHODS: The local committee for animal research approved this study. Four groups of six Hannover-Wistar rats were studied. Group A received normal saline; Group B, IV iron and Epo; Group C, gadodiamide, IV iron and Epo; and Group D, gadodiamide, IV iron, Epo and imatinib. Gadodiamide was administered at 10 mmol/kg of body weight for 5 consecutive days. Imatinib was administered at 50 mg/kg starting 3 days before gadodiamide injections and was continued for 50 days afterwards. Biopsies were taken 3 and 7 weeks after gadodiamide injection, and dermal histology was analyzed as well as gadolinium deposition as measured by inductively coupled plasma mass spectrometry. Additionally, rats treated with gadodiamide were observed for a total of 16 weeks. For comparison of cellularity, a linear mixed-effects model was used, and for metal deposition, an analysis of variance was used, which was corrected with a Tamhane correction for unequal variances. RESULTS: Rats treated with gadodiamide in addition to IV iron and Epo (group C) had worse skin lesions on histology (P<.001) compared to control animals (groups A and B). Treatment with imatinib resulted in decreased cellularity (group D vs C, P<.001), although there was no difference in the amount of deposited gadolinium (P>.5). Histology at 16 weeks demonstrated increased fibrosis and dermal calcifications, consistent with the clinical presentation of NSF. CONCLUSIONS: The administration of imatinib to rats treated with high-dose gadodiamide resulted in decreased lesion severity.
|
Authors | Thomas A Hope, Philip E Leboit, Whitney A High, Yanjun Fu, Robert C Brasch |
Journal | Magnetic resonance imaging
(Magn Reson Imaging)
Vol. 31
Issue 1
Pg. 139-44
(Jan 2013)
ISSN: 1873-5894 [Electronic] Netherlands |
PMID | 22898683
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 Elsevier Inc. All rights reserved. |
Chemical References |
- Benzamides
- Contrast Media
- Piperazines
- Protein Kinase Inhibitors
- Pyrimidines
- gadodiamide
- Imatinib Mesylate
- Gadolinium DTPA
|
Topics |
- Animals
- Benzamides
(therapeutic use)
- Contrast Media
(adverse effects)
- Gadolinium DTPA
(adverse effects)
- Imatinib Mesylate
- Male
- Nephrogenic Fibrosing Dermopathy
(drug therapy, pathology)
- Piperazines
(therapeutic use)
- Protein Kinase Inhibitors
(therapeutic use)
- Pyrimidines
(therapeutic use)
- Rats
- Rats, Wistar
- Treatment Outcome
|